Dr. Brian Salmons is the CEO & President and one of the founders of the company.
He has had twenty years experience in biotech, which commenced with him being appointed the Scientific Director of Bavarian Nordic (BN). He co-founded Austrianova Biotechnology GmbH in 2001 as well as Austrianova in 2007, where he also became the CEO.
Past experiences include being directly responsible for the initial Phase I/II clinical trials of an encapsulated cell product in pancreatic cancer in humans and mammary (breast) cancer in dogs as well as being part of the team that took Bavarian Nordic to its IPO in 1998.
Before moving to the commercial world in 1994, he spent 10 in years in academia.
Prof. Walter H. Günzburg, Ph.D. is the Chairman and one of the founders of the company.
He is also the Professor of Virology at the University of Veterinary Medicine, Vienna, Austria and formerly an Adjunct Professor at the National University of Singapore and director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development in Vienna.
Prior to founding Austrianova, he was the Chairman of the board of Austrianova Biotechnology GmbH and Austrianova Biomanufacturing AG. He has also been an advisor to Paktis (Germany) and Tocagen (USA), as well as a founder, board member and former Chairman of Virusure GmbH, a virus testing company located in Vienna, Austria.
He has also served as a member of German Federal Medical Association Ethics Committee for Gene Therapy (Kommission Somatische Gentherapie der Bundesärztekammer) since 1997 as well as a member of the European Academy for the Study of Consequences of Scientific and Technological Advances (since 1998).
Prof. Günzburg has more than 30 years experience in virology, and twenty years experience in cell therapy and bioencapsulation. He has published numerous peer reviewed scientific publications.
Dr John Dangerfield was appointed Chief Operating Officer of SG Austria in 2010, having previously been Head of Laboratory (2007-2010). John began his career in 1996 undertaking toxicology studies for the service provider Hammilton-Garrod in Bedfordshire, England. Following this he worked in Quality Control of injectable products for GE Healthcare (formerly Amersham Pharmacia Biotech) in Gloucester. He moved to Austria in 1997 and completed his PhD in molecular virology in 2001 from the University of Vienna. As a post-doctoral fellow at the University of Veterinary Medicine in Vienna from 2001-2007 he worked with bionanotech approaches for cancer therapy.
An active Council Member for the bio-industry alliance organisation BioSingapore from 2011-2014 and a committee member for the Singapore Stem Cell Consortium’s yearly international symposium in 2015, John has co-authored 16 peer-reviewed journal articles, 3 book chapters, and edited two books.
Louise Bussieres was appointed Chief Financial Officer of SG Austria in 2011. She is a certified Chartered Accountant with 30 years experience in accounting and finance. She is also a non-Executive Director of Innoheart Pte. Ltd., with other consulting interests as Principal of Bussieres Consulting Pte Ltd.
Prior to 2010, Ms. Bussieres was the Vice-President, Finance of LAB Research Inc. and Chief Financial Officer of LAB International Inc., two publicly traded Canadian pharmaceutical research organizations. From 1995 to 1999, she was Associate Director of the Experimental Biology Centre, the pre-clinical facility of the Institute of National Scientific Research of Quebec. Prior to 1995, Ms. Bussieres held several positions at KPMG, an international auditing and consulting firm.